Newsroom | 2258 results
Sorted by: Latest
-
Mave Health Raises $2.1M to Launch Focus and Stress Regulation Wearable
SAN FRANCISCO--(BUSINESS WIRE)--Mave Health, a neurotech company, announced $2.1 million in seed funding led by Blume Ventures with participation from other funds and angel investors, including Stanford Angels, Dhaval Shroff, and Raymond Russell. The company recently launched a non-invasive wearable headset built to improve focus, elevate mood, and regulate stress in just 20 minutes a day. Mave debuted with over 500 beta customers ahead of its public release last month. Based on self-reported d...
-
Identy.io Achieves Zero Attack Acceptance in DHS RIVR Face Liveness Evaluation, Leads Field on Speed and User Satisfaction
DOVER, Del.--(BUSINESS WIRE)--Identy.io today announced its results in the Active PAD evaluation of the 2025 Remote Identity Validation Rally (RIVR), conducted by the U.S. Department of Homeland Security (DHS) Science and Technology Directorate at the Maryland Test Facility (MdTF). Unlike the Passive PAD evaluation, which processes previously acquired samples, the Active PAD evaluation assesses the complete capture process with real users, capturing not only the effectiveness of the liveness sy...
-
Welldoc Bridges the Insulin Dosing Gap with New Real-World Evidence
COLUMBIA, Md.--(BUSINESS WIRE)--Welldoc®, a leader in AI-powered cardiometabolic health solutions, today announced new real-world evidence (RWE) demonstrating improved time in range (TIR) through the use of Welldoc’s Continuous Glucose Monitor (CGM)-informed insulin bolus calculator. For the millions of people who use bolus insulin, daily management is a burden. People with insulin-dependent diabetes make numerous, complex health-related decisions every day. When calculating a mealtime dose, in...
-
オムディアOmdia, 2025年世界ウェアラブルデバイス市場における出荷数メーカーランキング(速報値)を発表〜Xiaomi社が2020年以来の首位へ〜
ロンドン--(BUSINESS WIRE)--(ビジネスワイヤ) -- (ビジネスワイヤ) -- オムディア(Omdia)の最新調査によると、2025年の世界のウェアラブルデバイス市場の出荷台数は前年度比6%増加し、2億台を突破しました。Xiaomi社は2020年以降初めて首位を奪還し、年間出荷台数ベースで18%の市場シェアを獲得し、世界最大のウェアラブルベンダーとなりました。Apple社は17%でわずかに及ばず2位、HUAWEI社は16%で3位を堅守しました。また市場では競争の集約化が進み、Samsung社(9%)やGarmin社(5%)を含む上位5社が激しい攻防を繰り広げる中、トップ3の争いは特に上位3社が僅差で競り合っています。 オムディア(Omdiaのリサーチマネージャーであるシンシア・チェン氏は、「ウェアラブルデバイス市場は、ハードウェア主体の競争からエコシステム主体の競争へと転換しつつあります」と述べています。また同氏はこう指摘します。「上位3社のシェア差は1%未満であり、差別化の鍵はシームレスなクロスデバイス機能と、収益化可能な付加価値データサービスの提供に依存していま...
-
eClinical Solutions Appoints Lauren Whitsell as Chief Operating Officer and Venu Mallarapu as Chief Transformation and AI Officer
BOSTON--(BUSINESS WIRE)--eClinical Solutions LLC, a global provider of digital clinical software and services, today announced two additions to its C-suite with the hiring of Lauren Whitsell as Chief Operating Officer and appointment of Venu Mallarapu as Chief Transformation and AI Officer. The news comes following a growth investment from GI Partners, signaling strong momentum as the company deepens its product roadmap, further embedding AI and risk-based capabilities, and ensures future-ready...
-
フープ、WHOOP Advanced Labsのラインアップを拡充し、「Women’s Health Specialized Blood Biomarker Panel」を発表
ボストン--(BUSINESS WIRE)--(ビジネスワイヤ) -- ヒューマンパフォーマンス企業のフープ(WHOOP)は、提供開始予定の「Women's Health Specialized Blood Biomarker Panel」を含む、複数の新たな取り組みおよび臨床的根拠に基づく新機能を発表しました。フープが昨年開始した「WHOOP Advanced Labs」の「Baseline Panel」を基盤として、Women’s Health Specialized Blood Biomarker Panelでは、臨床的裏付けのある女性特有の血液バイオマーカー11項目を新たに追加しています。これにより、従来の女性向け健康検査では十分に測定されていない、または誤って解釈されがちな領域に対するより深い知見を提供します。フープはまた、新たな「Hormonal Symptom Insights and Predictions」のアップデートとともに、同社のサイクルモデリングの科学的根拠を詳述した包括的な「Menstrual Cycle White Paper」も併せて発表しました。 こ...
-
WHOOP amplía su oferta de WHOOP Advanced Labs y anuncia un panel de biomarcadores sanguíneos que se especializa en la salud femenina
BOSTON--(BUSINESS WIRE)--WHOOP, la empresa dedicada al rendimiento humano, presentó el día de hoy múltiples iniciativas y nuevas funciones que están respaldadas clínicamente, entre las que se incluye el próximo lanzamiento del Panel de biomarcadores sanguíneos especializados en salud femenina de la empresa. Basándose en el Panel de referencia de WHOOP Advanced Labs que se lanzó el año pasado, el Panel de biomarcadores sanguíneos especializados en salud femenina añade 11 biomarcadores sanguíneos...
-
Riassunto: WHOOP amplia l'offerta di WHOOP Advanced Labs, e annuncia un panello specializzato in biomarcatori ematici per la salute femminile
BOSTON--(BUSINESS WIRE)--WHOOP, l'azienda che si dedica alle prestazioni umane, ha presentato oggi diverse iniziative e nuove funzionalità clinicamente testate, tra cui il prossimo lancio del panello di biomarcatori ematici specializzati per la salute femminile dell'azienda. Sulla scia del pannello metabolico di base di WHOOP Advanced Labs lanciato l'anno scorso, il pannello specializzato di biomarcatori ematici per la salute femminile aggiunge 11 biomarcatori ematici specifici per le donne e c...
-
WHOOP expande oferta de serviços do WHOOP Advanced Labs com anúncio de um Painel Especializado em Biomarcadores Sanguíneos para Saúde Feminina
BOSTON--(BUSINESS WIRE)--WHOOP, empresa de desempenho humano, revelou hoje várias iniciativas e novos recursos com comprovação clínica, incluindo o próximo lançamento do Painel Especializado em Biomarcadores Sanguíneos para Saúde Feminina da empresa. Com base no painel básico WHOOP Advanced Labs lançado no ano passado, o Painel Especializado em Biomarcadores Sanguíneos para Saúde Feminina acrescenta 11 biomarcadores sanguíneos clinicamente comprovados e específicos para mulheres, ampliando a co...
-
WHOOP élargit son offre WHOOP Advanced Labs et annonce un panel de biomarqueurs sanguins spécialisés dans la santé des femmes
BOSTON--(BUSINESS WIRE)--WHOOP, la société spécialisée dans la performance humaine, a dévoilé aujourd’hui plusieurs initiatives et de nouvelles fonctionnalités cliniquement validées, notamment le lancement prochain de son panel de biomarqueurs sanguins spécialisés dans la santé des femmes. S’appuyant sur le panel de base WHOOP Advanced Labs lancé l’année dernière, le panel de biomarqueurs sanguins spécialisés dans la santé des femmes ajoute 11 biomarqueurs sanguins cliniquement validés et spéci...